followers
Read this study, please
A randomized, double-blind, and placebo-controlled 12-month efficacy study of CG 210 on hair diameter in male alopecia subjects already using Finasteride 1 mg
A Takeda1, S Harti2, J Liu2, L Zhang3 and A Sato4 1School of Medicine, Kitasato University, Kanagawa, Japan; 2Legacy Healthcare, Lausanne, Switzerland; 3Legacy Healthcare, Lausanne, Switzerland and 4Tokyo Memorial Clinic, Tokyo, Japan
Study rationale: Finesteride is often regarded as first-line treatment for male patients with androgenic alopecia (AGA). However, after several years of treatment, patients often reach a plateau.
CG210 is a GMP-grade topical botanical blend that has clinically demonstrated its efficacy to reestablish regular A/T ratio (and hence normal hair cycle) in AGA sufferers within 44 days. Its unique clinically validated mechanisms of action are: preventing premature apoptosis of cells in hair follicles; reducing micro-inflammation in the scalp, and increasing collagen content. We would expect to get a beneficial effect when combining oral Finasteride 1 mg (acting on androgens) with topical CG210 (acting on apoptosis and micro-inflammation, two key factors causing hair loss).
Hair diameter is an accurate clinical parameter for hair miniaturization (larger diameter=longer anagen phase=improved proportion of anagen vs telogen hair (A/T ratio)). An increase in hair diameter should also affect the cosmetic appearance and hair volume.
Objective: To evaluate the clinical effect of the topical anti-hair loss CG210 vs placebo on hair diameter in Japanese AGA patients already using Finasteride 1 mg for >3 years.
Study design: Randomized, double-blind, placebo-controlled, single-center, prospective, with two parallel groups.
Group A: Topical placebo provided to nine male alopecia subjects already taking Finasteride 1 mg treatment for >3 years.
Group B: Topical CG210 provided to seven male alopecia subjects already taking Finasteride 1 mg treatment for >3 years.
Results: Mean diameter of hair in the Finesteride+topical CG210 group versus Finesteride+placebo group increased by 36.9%. No adverse events were observed.
Conclusion: Application of topical CG210 in combination with Finasteride 1 mg demonstrated a statistically and clinically significant improvement in hair diameter and overall cosmetic appearance. Therefore, CG210 offers AGA sufferers an effective option to be used either alone to prevent and stop excessive hair loss or in combination with Finasteride to enhance patient outcome.
Att,